Daily reporting on US healthcare policy, technology, AI, cybersecurity and the business of care, verified from primary sources.
Looking for in-depth guides? Visit the Med Clinic X blog.
On 30 October 2026 the FDA approved updated labelling for three estradiol transdermal patches, removing outdated boxed-warning statements about cardiovascular disease, breast cancer and probable dementia, and set out steps to support supply as demand rises.
The FDA has approved Sun Pharma's Ilumya for adults with active psoriatic arthritis, adding a second use to a drug first approved in 2018 for plaque psoriasis, and making it the third IL-23 inhibitor approved for the joint condition.
The FDA has proposed the first update to US infant formula nutrient requirements since 1998, covering four nutrients in this first phase, alongside new contaminant testing data showing most samples with low or undetectable levels.
CMS has finalised a 2.7% increase in Medicare payments to dialysis facilities for 2027, lifting the base rate to $297.52 per treatment, with a wider low-volume adjustment and a higher home-dialysis training payment.
HHS will not take enforcement action against eligible pharmacies and physicians compounding six unapproved peptides while it finishes formal rulemaking, but none of the six has FDA approval, and the policy can be revisited if safety or quality problems emerge.
The hospital operator's third quarter shows the new arithmetic of 2026: admissions grew, revenue grew, and a shift toward uninsured patients still took about $400 million from pretax income.
The FDA has proposed letting sponsors cover multiple patient-specific genome-editing variants in a single application, while CMS plans to widen its Medicaid gene therapy negotiation model beyond sickle cell disease.
A six-month federal pilot will connect South Carolina rural hospitals with free cybersecurity hardware and services from major technology firms, starting with network defence, backup devices and legacy equipment replacement.
HHS and ONC have released the HTI-5 final rule, removing 14 of the 60 health IT certification criteria and revising seven more, in a narrower package than the 34 removals proposed in December 2025.
The FDA has approved talazoparib (Talzenna) in combination with enzalutamide (Xtandi) for adults with metastatic prostate cancer that remains sensitive to hormone therapy and carries homologous recombination repair gene mutations.
The share of working-age Americans without health insurance rose from 8.9% in 2024 to 11.2% in 2026, according to the Commonwealth Fund's 2026 Biennial Health Insurance Survey, with nearly half of working-age adults now inadequately insured.
OpenAI has acquired Orchestra Bio, a platform whose AI agents help biopharmaceutical teams coordinate drug development programmes, and is folding its team and technology into Rosalind, its life-sciences models and tools.